AR126970A1 - Polipétidos - Google Patents

Polipétidos

Info

Publication number
AR126970A1
AR126970A1 ARP220102384A ARP220102384A AR126970A1 AR 126970 A1 AR126970 A1 AR 126970A1 AR P220102384 A ARP220102384 A AR P220102384A AR P220102384 A ARP220102384 A AR P220102384A AR 126970 A1 AR126970 A1 AR 126970A1
Authority
AR
Argentina
Prior art keywords
polypeptide
lpar1
construct
expression vector
polynucleotide sequence
Prior art date
Application number
ARP220102384A
Other languages
English (en)
Inventor
Joseph Illingworth
David Llewellyn
Megan Ingham
Michael Steward
Original Assignee
Djs Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Djs Antibodies Ltd filed Critical Djs Antibodies Ltd
Publication of AR126970A1 publication Critical patent/AR126970A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan, entre otras cosas, polipéptidos como anticuerpos o fragmentos de los mismos que se unen a LPAR1. Reivindicación 1: Un polipéptido que se une a LPAR1, en el que el polipéptido es un inhibidor de LPAR1. Reivindicación 29: Un Constructo que comprende el polipéptido de cualquiera de las reivindicaciones 1 a 28. Reivindicación 30: Una composición farmacéutica que comprende el polipéptido o el constructo de cualquiera de las reivindicaciones 1 a 29, junto con un diluyente o portador farmacéuticamente aceptable. Reivindicación 33: Una secuencia de polinucleótidos que codifica el polipéptido o el constructo de cualquiera de las reivindicaciones 1 a 29. Reivindicación 34: Un vector de expresión que comprende la secuencia de polinucleótidos de la reivindicación 33. Reivindicación 35: Una célula que comprende la secuencia de polinucleótidos de la reivindicación 33 o el vector de expresión de la reivindicación 34.
ARP220102384A 2021-09-02 2022-09-02 Polipétidos AR126970A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21194607 2021-09-02
EP22155472 2022-02-07

Publications (1)

Publication Number Publication Date
AR126970A1 true AR126970A1 (es) 2023-12-06

Family

ID=83691474

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102384A AR126970A1 (es) 2021-09-02 2022-09-02 Polipétidos

Country Status (8)

Country Link
US (2) US20230181671A1 (es)
AR (1) AR126970A1 (es)
AU (1) AU2022338282A1 (es)
CA (1) CA3230808A1 (es)
CO (1) CO2024004055A2 (es)
IL (1) IL311184A (es)
TW (1) TW202328189A (es)
WO (1) WO2023031615A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024085081A1 (ja) * 2022-10-18 2024-04-25 株式会社エヌビィー健康研究所 抗体、核酸、細胞、及び医薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008153072A1 (ja) * 2007-06-12 2008-12-18 Riken 骨・関節疾患感受性遺伝子およびその用途
CA3086659A1 (en) 2007-12-26 2009-07-09 Xencor, Inc. Fc variants with altered binding to fcrn
WO2018035107A2 (en) 2016-08-15 2018-02-22 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life

Also Published As

Publication number Publication date
CO2024004055A2 (es) 2024-05-10
AU2022338282A1 (en) 2024-03-14
WO2023031615A1 (en) 2023-03-09
US20230181671A1 (en) 2023-06-15
TW202328189A (zh) 2023-07-16
CA3230808A1 (en) 2023-03-09
IL311184A (en) 2024-04-01
US20240123020A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
AR126987A2 (es) Inmunoconjugados
AR126970A1 (es) Polipétidos
PE20211400A1 (es) Constructos de anticuerpos para cldn18.2 y cd3
CL2008002861A1 (es) Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion.
AR076018A1 (es) Anticuerpos multiespecificos especialmente biespecificos
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
CO7170123A2 (es) Complejo del factor viii con xten y proteína del factor von willebrand y sus usos
ECSP10010142A (es) Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
PE20171336A1 (es) Anticuerpos contra tau y sus usos
AR119902A1 (es) Proteínas de fusión terapéuticas
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
PE20190415A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos
PE20220708A1 (es) Anticuerpos anti-cd73
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
MX2018013306A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
ECSP23088752A (es) Anticuerpos anti-adgre2 y usos de los mismos
CU20210105A7 (es) Agonistas de il2
CL2020002364A1 (es) Inhibidores de yap1 que dirigen la interacción de yap1 con oct4.
PE20180490A1 (es) Moleculas de fusion
CU20220017A7 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.